MOHAMMED KABIR: Open Payments
NPI 1326131715 · TROY, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,454 in 23 payments from 12 companies in 2025. Trend: 2023 $1,166 · 2024 $2,389 · 2025 $2,454
Food & beverage: $2,454
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 5 | $610 |
| Amgen Inc. | 3 | $360 |
| Janssen Pharmaceuticals, Inc | 3 | $269 |
| Novo Nordisk Inc | 2 | $246 |
| Vanda Pharmaceuticals Inc. | 2 | $209 |
| Supernus Pharmaceuticals, Inc. | 2 | $142 |
| Janssen Biotech, Inc. | 1 | $125 |
| AstraZeneca Pharmaceuticals LP | 1 | $125 |
| Lilly USA, LLC | 1 | $123 |
| AKEBIA THERAPEUTICS INC | 1 | $123 |
Products named: INVEGA SUSTENNA, EMBLAVEO, Ozempic, VRAYLAR, FANAPT, Qelbree, RYBREVANT, AVYCAZ.
Industry payments across NY — which companies pay providers there.
